ArticleFrontiers in oncology2023

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma.

Laura Rosiñol et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.